Glucagon-Like Peptide-1 Analogs Associated with a Reduced Risk of Legal Blindness in Type 2 Diabetics with Cardiovascular Risks.

After propensity score matching, each cohort included 350,536 patients (mean age 58.7 ± 12.6 years; 61.6% female).

There was no significant difference in ischemic optic neuropathy incidence between cohorts at 1 year (HR 0.872, 95% CI 0.627-1.212), 3 years (HR 1.002, 95% CI 0.792-1.268), or 5 years (HR 0.978, 95% CI 0.789-1.211).